Limitations
obesity, Obesity
OBESITY, OBESITY
Limitations to this trial include a higher percentage of women with obesity who were assigned to arm 1, while a higher percentage of women who had prior exposure to chemotherapy and/or everolimus were assigned to arm 2. Obesity, with its associated comorbidities, as well as prior exposure to chemotherapy, may have negatively affected tolerability to alisertib and the ability to continue receiving treatment. Additionally, the study cohort was confined to postmenopausal women, and participation of those of racial and ethnic minority groups was suboptimal, thus limiting generalizability. Finally, the sample size for the correlative studies was small, which limits interpretation.